GAITHERSBURG, Md., Feb. 1 /PRNewswire-FirstCall/ -- Iomai Corporation, a biopharmaceutical company, today announced the pricing of the initial public offering of 5,000,000 shares of its common stock at a public offering price of $7.00 per share. All of the shares in the offering are being sold by Iomai. In addition, Iomai has granted the underwriters an option to purchase up to an additional 750,000 shares to cover over-allotments, if any. Iomai common stock is expected to begin trading today on The NASDAQ National Market under the symbol “IOMI.” UBS Investment Bank is acting as the sole book-running manager. SG Cowen & Co. is acting as co-lead manager and First Albany Capital and Susquehanna Financial Group are co-managers.
This offering is only being made by means of a prospectus, which may be obtained from UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171 (telephone number: 212-821-3000).
About Iomai
Iomai is a biopharmaceutical company focused on the discovery, development and commercialization of vaccines and immunostimulants delivered to the skin using the proprietary process known as transcutaneous immunization.
Iomai Corporation
CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, of Iomai Corporation, +1-301-556-4478 orinvestors@iomai.com; or Daryl Messinger of WeissComm Partners, Inc.,+1-415-999-2361 or daryl@weisscommpartners.com, for Iomai Corporation
